金吾财讯 | 创新药股延续升势，博安生物(06955)涨10.10%，绿叶制药(02186)涨4.70%，药明生物(02269)涨4.04%，康方生物(09926)涨3.61%，和黄医药(00013)涨3.14%，三生制药(01530)涨3.20%，翰森制药(03692)涨2.87%，石药集团(01093)涨3.06%。消息面上，国泰海通发研报指，近期BD催化不断，创新药出海逻辑稳健，行情有望持续。近期BD催化不断，如翰森制药6月2日公告与再生元订立许可协议，授予再生元开发、生产及商业化HS-20094(GLP-1/GIP)的海外独占许可，翰森制药将获得8000万美元首付款+最高19.3亿美元里程碑+双位数销售分成；智翔金泰6月4日公告与CullinanTherapeutics签署授权协议，授予其GR1803注射液(BCMA/CD3双抗)大中华区域以外区域权益，智翔金泰将获得2000万美元首付款+最高2.92亿美元的开发和注册里程碑+最高4亿美元的基于净销售额的里程碑，以及基于净销售额的最高中双位数的分级特许权使用费。近期频繁落地的BD验证了跨国药企对中国优质创新药资产的需求远大于对地缘风险的担忧，创新药出海逻辑稳健，有望继续催化创新药行情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.